Pasireotide for Cushing's Disease
Peptide Therapeutics
5 somatostatin receptors
Pasireotide binds four of five somatostatin receptor subtypes with high affinity, including SSTR5, the dominant receptor on ACTH-secreting pituitary adenomas that older somatostatin analogs largely miss.
Li et al., Acta Pharmacologica Sinica, 2024
Li et al., Acta Pharmacologica Sinica, 2024
View as imageCushing's disease is caused by a benign pituitary tumor that secretes too much ACTH, driving the adrenal glands to overproduce cortisol. The excess cortisol damages nearly every organ system: bones thin, blood sugar rises, blood pressure climbs, muscles waste, and infections become more frequent. Surgery to remove the pituitary adenoma is the first-line treatment, but it fails or the disease recurs in 20-30% of patients. For decades, no drug directly targeted the tumor itself. Older somatostatin analogs like octreotide worked well for growth hormone-secreting tumors but had minimal effect on ACTH-secreting corticotroph adenomas. The reason: corticotroph tumors predominantly express somatostatin receptor subtype 5 (SSTR5), while octreotide primarily binds SSTR2.[1] Pasireotide (Signifor, developed by Novartis) changed that equation. It binds SSTR5 with 40-fold higher affinity than octreotide and became the first pituitary-directed medication approved for Cushing's disease in 2012.[2] This article covers how pasireotide works, what the clinical data shows, and why its signature side effect, hyperglycemia, remains a major clinical challenge. For broader context on somatostatin biology, see our article on somatostatin, the peptide that brakes growth hormone. For a deeper look at the ACTH-cortisol axis, see our dedicated coverage.
Key Takeaways
- Pasireotide binds somatostatin receptor 5 (SSTR5) with 40-fold higher affinity than octreotide, which primarily targets SSTR2; this matters because corticotroph adenomas predominantly express SSTR5 (Li et al., Acta Pharmacol Sin, 2024)
- In the phase 3 NEJM trial, pasireotide 600 or 900 mcg twice daily normalized urinary free cortisol in 15-26% of patients at 6 months, with a median UFC reduction of approximately 50% by month 2 (Ceccato et al., Ther Clin Risk Manag, 2015)
- Hyperglycemia occurred in 73% of patients in the phase 3 trial, making it the most significant adverse effect; the mechanism involves direct SSTR5-mediated suppression of insulin secretion (Sato et al., Sci Rep, 2025)
- GLP-1 receptor agonists appear to be the most effective treatment for pasireotide-induced hyperglycemia based on the mechanism of impaired incretin signaling (Stormann et al., Front Endocrinol, 2024)
- A long-acting intramuscular formulation (Signifor LAR, 10-30 mg monthly) was later approved for both Cushing's disease and acromegaly, improving adherence over twice-daily injections
- Approximately 8% of patients with difficult-to-control type 2 diabetes may have undiagnosed hypercortisolism, suggesting Cushing's disease is more prevalent than recognized (Buse et al., Diabetes Care, 2025)
Why Octreotide Fails in Cushing's Disease
To understand pasireotide, you need to understand why the first-generation somatostatin analogs do not work for Cushing's disease. Somatostatin is a natural peptide that inhibits hormone secretion from multiple cell types. There are five somatostatin receptor subtypes (SSTR1-5), each with different expression patterns across tissues.[3]
Growth hormone-secreting pituitary adenomas (which cause acromegaly) predominantly express SSTR2. Octreotide and lanreotide bind SSTR2 with high affinity, which is why they effectively suppress growth hormone in acromegaly and control symptoms in carcinoid syndrome.
ACTH-secreting corticotroph adenomas are different. They predominantly express SSTR5, with lower levels of SSTR2 and SSTR1. Adding to the problem, the high cortisol environment of Cushing's disease further downregulates SSTR2 expression on these tumors while leaving SSTR5 expression relatively preserved.[1] This means the receptor that octreotide targets is both sparse and actively suppressed in Cushing's disease, while the receptor it largely ignores (SSTR5) is the one that could actually control ACTH secretion.
How Pasireotide Works
Pasireotide is a cyclohexapeptide (cyclic six-amino-acid peptide) that binds four of the five somatostatin receptor subtypes. Its binding affinity profile compared to octreotide is dramatic: 40-fold higher for SSTR5, 30-fold higher for SSTR1, and 5-fold higher for SSTR3, with about 2-fold lower affinity for SSTR2.[2]
Li et al. (2024) resolved the crystal structure of SSTR5 bound to pasireotide and octreotide, revealing why pasireotide preferentially activates this receptor. Key interactions between pasireotide's Tyr(Bzl) and D-Trp residues and specific binding pockets on SSTR5 create a tighter molecular fit than octreotide achieves. The structural data also showed that SSTR5's extracellular loops adopt a distinct conformation when binding pasireotide compared to octreotide, which may explain the functional selectivity differences between the two drugs.[1]
On corticotroph cells, pasireotide binding to SSTR5 triggers several downstream effects: inhibition of ACTH secretion through reduced cAMP signaling, suppression of proopiomelanocortin (POMC) gene expression (the precursor protein from which ACTH is cleaved), and antiproliferative effects on the tumor cells themselves. The antiproliferative action involves both cell cycle arrest and pro-apoptotic signaling, suggesting pasireotide may do more than just suppress hormone output; it may also slow tumor growth.
Ochiai et al. (2023) demonstrated that chemical glycosylation of somatostatin analogs can improve their pharmacokinetic properties, including solubility and metabolic stability. These modifications represent an ongoing effort to develop next-generation somatostatin peptides with improved receptor selectivity and duration of action.[9]
Li et al. (2024) also resolved the structure of SSTR5 bound to a separate activation mechanism, showing how the receptor couples to Gi proteins to inhibit adenylyl cyclase. This structural work provides a foundation for designing more selective SSTR5 agonists that might retain pasireotide's efficacy in Cushing's disease while reducing off-target effects on pancreatic beta cells.[10]
Clinical Efficacy in Cushing's Disease
The pivotal evidence for pasireotide in Cushing's disease comes from a 12-month, double-blind phase 3 trial published in the New England Journal of Medicine (Colao et al., 2012). Patients with persistent or recurrent Cushing's disease (n=162) received pasireotide 600 or 900 mcg subcutaneously twice daily.[2]
At 6 months, the primary endpoint of normalized urinary free cortisol (UFC equal to or below the upper limit of normal) was achieved by 14.6% of the 600 mcg group and 26.3% of the 900 mcg group. The median UFC reduction was approximately 50% by month 2 and remained stable through month 12. In patients who entered a long-term extension, 50% had controlled UFC at 12 months and 34.5% at 24 months.
Beyond cortisol normalization, pasireotide produced clinically meaningful improvements in the systemic manifestations of Cushing's disease: blood pressure decreased, total cholesterol declined, body weight dropped, and body mass index improved. These changes reflect the downstream effects of reducing chronic cortisol excess.
Ceccato et al. (2015) reviewed clinical use data and noted that even patients who did not achieve full UFC normalization often experienced partial cortisol reductions sufficient to improve clinical symptoms. A 50% reduction in cortisol, even if still above normal, can meaningfully reduce the cardiovascular and metabolic burden of the disease.[2]
Real-World Experience
The phase 3 trial results represent efficacy under controlled conditions. Real-world data from 2025 provides a more nuanced picture. A retrospective cohort study of patients treated with subcutaneous pasireotide between 2012 and 2024 at a single center found that response rates in clinical practice are roughly consistent with trial data, though treatment discontinuation due to hyperglycemia was higher than in the controlled trial setting. Some patients who initially responded lost efficacy over time, a phenomenon that may relate to receptor desensitization or tumor evolution. However, re-starting pasireotide after a break did not reliably restore the original response in all cases.
Combination approaches have emerged in clinical practice. Pasireotide is sometimes combined with cabergoline (a dopamine agonist) or ketoconazole (an adrenal steroidogenesis inhibitor) when monotherapy produces insufficient cortisol reduction. These combinations target different nodes in the cortisol production pathway simultaneously and can improve biochemical control rates beyond what any single agent achieves alone.
The Hyperglycemia Problem
Hyperglycemia is pasireotide's most significant adverse effect and the primary barrier to broader adoption. In the phase 3 trial, hyperglycemia-related adverse events occurred in 73% of patients (118 of 162). The mechanism is well characterized: SSTR5 is expressed on pancreatic beta cells and is involved in regulating insulin secretion.
Sato et al. (2025) investigated this mechanism and found that pasireotide directly suppresses both GLP-1-mediated and glucose-stimulated insulin secretion through SSTR5 activation on pancreatic islets. The incretin pathway, which normally amplifies insulin release in response to meals, is particularly affected.[4]
Taki et al. (2025) conducted a comprehensive case analysis of glycemic effects and found that pasireotide-induced hyperglycemia occurs rapidly (within the first weeks of treatment), is dose-dependent, and can be severe enough to require insulin therapy in some patients. However, long-term data showed that glycemic control often stabilizes over months of treatment, and some patients' hyperglycemia improves as their cortisol levels decrease (since cortisol itself causes insulin resistance).[5]
Managing Pasireotide-Induced Hyperglycemia
Stormann et al. (2024) published an expert consensus on managing this side effect. Their key recommendation: GLP-1 receptor agonists are the most mechanistically appropriate treatment for pasireotide-induced hyperglycemia because they directly counteract the suppressed incretin signaling that causes it.[6]
The approach involves proactive glucose monitoring from the start of pasireotide therapy, early initiation of metformin, and escalation to GLP-1 receptor agonists (such as liraglutide or semaglutide) if needed. DPP-4 inhibitors can also be used but appear less effective because pasireotide suppresses the entire incretin axis rather than just accelerating incretin degradation. In Sato's case report, switching from a DPP-4 inhibitor to a GLP-1 analog successfully controlled hyperglycemia that had been resistant to the prior approach.[4]
Kargutkar (2025) reported a case where the combination of levoketoconazole (a cortisol synthesis inhibitor) and semaglutide in a patient with mild hypercortisolism produced weight loss exceeding what either treatment would be expected to achieve alone, suggesting potential synergistic benefit in patients with overlapping cortisol excess and metabolic dysfunction.[7]
Formulations: Twice-Daily vs. Long-Acting
Pasireotide is available in two formulations:
Signifor (subcutaneous): 300, 600, or 900 mcg twice daily. This was the original formulation approved for Cushing's disease. The twice-daily injection schedule creates an adherence burden, particularly for a chronic condition requiring long-term treatment.
Signifor LAR (intramuscular): 10, 20, 30, or 40 mg once monthly. This long-acting release formulation was approved for acromegaly (where pasireotide's multi-receptor binding profile offers advantages over octreotide for SSTR2-resistant cases) and subsequently for Cushing's disease. Monthly dosing substantially improves adherence and quality of life. Like desmopressin for diabetes insipidus, pasireotide represents a case where modifying a natural peptide's structure to change its receptor selectivity and duration of action transformed a biological signal into a targeted therapeutic.
Both formulations share the same receptor binding profile and hyperglycemia risk. The LAR formulation provides more stable drug levels, which may reduce peaks in adverse effects.
Pasireotide in the Broader Treatment Landscape
Pasireotide is one of several medical therapies available for Cushing's disease, each targeting a different part of the cortisol production pathway:
Pituitary-targeted (pasireotide, cabergoline): acts directly on the tumor to reduce ACTH secretion. Pasireotide is the only FDA-approved option in this category.
Adrenal steroidogenesis inhibitors (ketoconazole, osilodrostat, metyrapone, levoketoconazole): block cortisol synthesis in the adrenal glands regardless of ACTH levels.
Glucocorticoid receptor antagonist (mifepristone): blocks cortisol's action at the receptor level without reducing cortisol production.
Pasireotide is the only approved treatment that directly targets the pituitary tumor causing the disease. This distinction matters because reducing ACTH secretion at the source also reduces the risk of tumor growth over time, a benefit that adrenal-targeted therapies do not provide.[2]
The Hidden Prevalence of Hypercortisolism
One reason pasireotide's market remains relatively small is that Cushing's disease is considered rare, with an estimated incidence of 1-3 per million per year. But Buse et al. (2025) challenged this assumption. In a prospective study of patients with difficult-to-control type 2 diabetes (HbA1c 7.5-11.5% on two or more glucose-lowering medications), approximately 8% had biochemical evidence of hypercortisolism.[8]
If confirmed in larger studies, this finding has significant implications. Millions of people worldwide have type 2 diabetes that resists standard treatment. If a meaningful fraction have undiagnosed cortisol excess contributing to their metabolic dysfunction, targeted screening could identify patients who would benefit from specific cortisol-lowering therapies rather than escalating diabetes medications that address a downstream effect rather than the cause.
Limitations
The evidence base for pasireotide in Cushing's disease has notable gaps.
Low normalization rates. Full UFC normalization occurred in only 15-26% of patients in the phase 3 trial. While partial cortisol reduction has clinical value, this means most patients do not achieve complete biochemical control with pasireotide alone.
Hyperglycemia limits use. The 73% rate of hyperglycemia-related events means most patients require additional glucose-lowering medication, adding complexity and cost to treatment.
No head-to-head comparisons. There are no randomized trials comparing pasireotide directly against osilodrostat, levoketoconazole, or cabergoline. Treatment selection currently relies on clinical judgment, side effect profiles, and individual patient factors rather than comparative efficacy data. This gap is particularly notable given that osilodrostat has shown higher UFC normalization rates in its own phase 3 trial, though direct comparison with different patient populations is unreliable.
Limited tumor shrinkage data. While pasireotide has antiproliferative effects in vitro, data on tumor volume reduction in human Cushing's disease trials is limited. For acromegaly, the data on somatostatin analog effects on tumor size is more extensive.
The Bottom Line
Pasireotide is the first and only pituitary-targeted drug approved for Cushing's disease. Its multi-receptor somatostatin binding profile, particularly its 40-fold higher affinity for SSTR5 compared to octreotide, allows it to suppress ACTH secretion from corticotroph adenomas that older somatostatin analogs cannot reach. The tradeoff is a 73% rate of hyperglycemia driven by SSTR5-mediated insulin suppression. Full cortisol normalization occurs in 15-26% of patients, with clinically meaningful partial reductions in many more. GLP-1 receptor agonists have emerged as the most mechanistically appropriate treatment for the hyperglycemia it causes.